Regeneron Pharmaceuticals

Get in the Ideas Business.
At Regeneron we believe that when the right idea finds the right team, powerful change is possible.
As we work together to discover, invent, and develop biopharmaceutical medicines, we’re creating whole new ways of thinking about science, manufacturing and commercialization. And whole new ways of thinking about health.
So connect with us. Tell us about you. Learn more about our life-changing medicines. And join us, as we build a future we believe in.

Company Growth (employees)
Type
Public
HQ
Tarrytown, US
Founded
1988
Size (employees)
5,400 (est)
Regeneron Pharmaceuticals was founded in 1988 and is headquartered in Tarrytown, US

Regeneron Pharmaceuticals Office Locations

Regeneron Pharmaceuticals has offices in Tarrytown, Rensselaer, Bernards, Limerick and in 1 other location
Tarrytown, US (HQ)
777 Old Saw Mill River Rd
Dublin, IE
Harcourt Centre Harcourt St
Bernards, US
110 Allen Rd
Rensselaer, US
81 Columbia Turnpike

Regeneron Pharmaceuticals Data and Metrics

Regeneron Pharmaceuticals Financial Metrics

Regeneron Pharmaceuticals's revenue was reported to be $1.3 b in Q1, 2017
USD

Revenue (Q1, 2017)

1.3 b

Gross profit (Q1, 2017)

1.3 b

Gross profit margin (Q1, 2017), %

95%

Net income (Q1, 2017)

248.9 m

EBIT (Q1, 2017)

430.5 m

Market capitalization (18-Aug-2017)

54.3 b

Cash (31-Mar-2017)

811.8 m
Regeneron Pharmaceuticals's current market capitalization is $54.3 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

2.1 b2.8 b4.1 b4.9 b

Revenue growth, %

34%46%18%

Cost of goods sold

118 m129 m241.7 m194.6 m

Gross profit

2 b2.7 b3.9 b4.7 b

Gross profit Margin, %

94%95%94%96%

R&D expense

2.1 b

Operating expense total

2.1 b

EBIT

760 m838.4 m1.3 b1.3 b

EBIT margin, %

36%30%31%27%

Interest expense

46.4 m37.4 m14.2 m7.2 m

Pre tax profit

713.4 m775.7 m1.2 b1.3 b

Income tax expense

(289 m)(427.7 m)(589 m)(434.3 m)

Net Income

424.4 m348.1 m636.1 m895.5 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

665.7 m725.8 m869.6 m998.6 m1.1 b1.2 b1.2 b1.2 b1.3 b

Cost of goods sold

29.9 m33.7 m42.6 m60.9 m67.2 m78.9 m41.2 m29.9 m61.3 m

Gross profit

635.8 m692.1 m827 m937.8 m1.1 b1.1 b1.2 b1.2 b1.3 b

Gross profit Margin, %

96%95%95%94%94%93%97%98%95%

R&D expense

294.5 m337.7 m343.1 m390.3 m425.9 m470.1 m559.9 m543 m507.4 m

EBIT

222.4 m182.7 m283.6 m344.9 m392.4 m329.3 m291.6 m362.8 m430.5 m

EBIT margin, %

33%25%33%35%35%27%24%30%33%

Pre tax profit

203.1 m176.1 m276.5 m328 m393.3 m330.2 m292.3 m365.9 m432.3 m

Net Income

158.2 m237.9 m76 m270.7 m481.1 m165.7 m377.6 m642.4 m248.9 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

535.6 m648.7 m809.1 m535.2 m

Inventories

70.4 m128.9 m238.6 m399.4 m

Current Assets

1.8 b2.2 b2.9 b3.2 b

PP&E

2.1 b

Total Assets

3 b3.9 b5.6 b7 b

Accounts Payable

250.9 m484.2 m644.1 m879.1 m

Current Liabilities

298.8 m654.7 m811.2 m1.2 b

Total Liabilities

2.5 b

Common Stock

2 k2 k2 k2 k

Additional Paid-in Capital

2 b2.4 b3.1 b3 b

Retained Earnings

(92.7 m)255.4 m852.7 m1.7 b

Total Equity

2 b2.5 b3.7 b4.4 b

Financial Leverage

1.5 x1.5 x1.5 x1.6 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

600.1 m646.6 m507.9 m390.6 m654.6 m604.2 m646.5 m920.4 m811.8 m

Inventories

109.9 m120.3 m133.9 m171.3 m190.7 m303.3 m316.1 m345.6 m466.6 m

Current Assets

1.9 b2.2 b2.3 b2.3 b2.7 b3.1 b3.2 b3.5 b3.7 b

PP&E

1.7 b1.8 b1.9 b2.3 b

Total Assets

3.5 b3.7 b4.2 b4.5 b5.2 b5.9 b6.2 b6.8 b7.8 b

Accounts Payable

283.4 m338 m462.8 m529.5 m577.4 m733.3 m759.6 m714.9 m1.1 b

Current Liabilities

351.6 m410.2 m536.1 m601.5 m735 m919.7 m951.6 m961.2 m1.3 b

Common Stock

2 k2 k2 k2 k2 k2 k2 k2 k2 k

Additional Paid-in Capital

2.3 b2.4 b2.8 b3.1 b2.9 b3 b3.2 b3.3 b3.2 b

Retained Earnings

65.5 m145.2 m292.7 m487.3 m697.7 m1 b1.2 b1.5 b2 b

Total Equity

2.4 b2.6 b3 b3.3 b3.3 b3.8 b4.1 b4.5 b4.9 b

Financial Leverage

1.5 x1.5 x1.4 x1.4 x1.6 x1.6 x1.5 x1.5 x1.6 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

424.4 m348.1 m636.1 m895.5 m

Depreciation and Amortization

41.2 m52.7 m74.9 m104.7 m

Inventories

(48 m)(61 m)(110 m)(149.8 m)

Cash From Operating Activities

583.6 m743.2 m1.3 b1.5 b

Capital Expenditures

(156.3 m)(333 m)(677.9 m)(511.9 m)

Cash From Investing Activities

(355.5 m)

Cash From Financing Activities

(209.3 m)(262.8 m)(700.4 m)

Interest Paid

23.8 m20.6 m10.6 m5.5 m

Income Taxes Paid

59.8 m276.1 m481.4 m

Free Cash Flow

740 m1.1 b2 b961.5 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

158.2 m237.9 m76 m270.7 m481.1 m165.7 m377.6 m642.4 m248.9 m

Depreciation and Amortization

24.5 m38.6 m16 m31.3 m52 m23 m48 m75.8 m38.1 m

Inventories

(37.3 m)(50.9 m)(5.9 m)(49.9 m)(81.5 m)(62.3 m)(72.9 m)(99.7 m)(69.7 m)

Cash From Operating Activities

381.3 m544.9 m(87.5 m)156.1 m1 b29.3 m444.5 m1.1 b355.9 m

Capital Expenditures

(135.7 m)(215.5 m)(114.2 m)(354.1 m)(500.2 m)(104.1 m)(242.9 m)(361.5 m)(50.5 m)

Cash From Investing Activities

(354.4 m)(477.4 m)(129.5 m)(501.1 m)(784.3 m)(43.7 m)(369.7 m)(775.5 m)(140.1 m)

Cash From Financing Activities

37.6 m43.5 m76.2 m86.9 m(258.8 m)(190.5 m)(237.4 m)60.8 m

Free Cash Flow

245.6 m329.4 m(201.7 m)(198 m)548.8 m(74.8 m)201.6 m734 m305.4 m
USDY, 2017

Revenue/Employee

244.3 k

Financial Leverage

1.6 x

Regeneron Pharmaceuticals Market Value History

Regeneron Pharmaceuticals Median Salaries

Source: 186 public H-1B filings from Regeneron Pharmaceuticals

Traffic Overview of Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Online and Social Media Presence

Regeneron Pharmaceuticals News and Updates

Domino’s stock has outperformed Google, Facebook, Apple, and Amazon this decade

It’s 2010. You’re an eager investor presented a choice between two stocks: Google or Domino’s pizza company. Where do you put your money? You should…

US Stocks Dip as December Hiring Report Fails to Inspire

U.S. stocks are dipping Friday morning after a solid but unspectacular hiring report for December. While employers kept hiring and hourly pay jumped, it wasn't enough to allay investors' concerns about slow economic growth. Bond yields are climbing as investors think the report shows interest rates …

Regeneron, Sanofi to Appeal US Judge's Ban on Cholesterol Drug Sales

Regeneron Pharmaceuticals Inc and Sanofi SA said on Thursday they would appeal the U.S. District Court ruling which banned the two companies from selling their cholesterol drug, Praluent, on grounds of patent infringement.

Wary Drug Makers Move to Fend Off Further Attacks Under Donald Trump

Even before the president-elect vowed “to bring down drug prices,” many companies began taking a pre-emptive approach on pricing.

Donald Trump Sent Biotech Stocks Plummeting with These 16 Words

His drug price comments rattled investors.

Mylan’s CEO Is Right—Pharma’s Price Hikes Could Ultimately Lead to Some Good

From within or without, change may actually be coming.
Show more

Regeneron Pharmaceuticals Company Life and Culture

You may also be interested in